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Abstract
In patients with chronic liver diseases, identification 
of significant liver fibrosis and cirrhosis is essential for 
determining treatment strategies, assessing therapeu-
tic response, and stratifying long-term prognosis. Al-
though liver biopsy remains the reference standard for 
evaluating the extent of liver fibrosis in patients with 
chronic liver diseases, several non-invasive methods 
have been developed as alternatives to liver biopsies. 
Some of these non-invasive methods have demon-
strated clinical accuracy for diagnosing significant fi-
brosis or cirrhosis in many cross-sectional studies with 
the histological fibrosis stage as a reference standard. 
However, non-invasive methods cannot be fully vali-
dated through cross-sectional studies since liver biopsy 
is not a perfect surrogate endpoint marker. Accord-
ingly, recent studies have focused on assessing the 
performance of non-invasive methods through long-
term, longitudinal, follow-up studies with solid clinical 
endpoints related to advanced stages of liver fibrosis 
and cirrhosis. As a result, current view is that these 
alternative methods can independently predict future 
cirrhosis-related complications, such as hepatic de-
compensation, liver failure, hepatocellular carcinoma, 
or liver-related death. The clinical role of non-invasive 
models seems to be shifting from a simple tool for pre-
dicting the extent of fibrosis to a surveillance tool for 
predicting future liver-related events. In this article, we 
will summarize recent longitudinal studies of non-inva-
sive methods for predicting forthcoming complications 
related to liver cirrhosis and discuss the clinical value 
of currently available non-invasive methods based on 
evidence from the literature.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: In this article, we summarized recent lon-
gitudinal studies of non-invasive methods - including 
transient elastography, European Liver Fibrosis scoring 
system, Fibrotest, and acoustic radiation force impulse 
technique - for predicting forthcoming complications 
related to liver cirrhosis. We also discussed the clini-
cal value of currently available non-invasive methods 
based on evidence from the literature and finally pro-
posed areas for future research directions.
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INTRODUCTION
Viral hepatitis accounts for the majority of  chronic 
liver diseases (CLDs) worldwide[1-4]. In the absence of  
appropriate therapeutic interventions, CLD can prog-
ress to significant liver fibrosis or cirrhosis, resulting 
in complications, such as portal hypertension, ascites, 
or hepatocellular carcinoma (HCC)[5-7]. In recent years, 
secondary prevention of  CLD progression to significant 
liver fibrosis or cirrhosis has been quite successful due 
to the development and application of  antiviral thera-
pies. However, liver-related events (LREs), especially cir-
rhosis-related complications, occur despite appropriate 
management with antiviral treatments. These LREs are 
clinically important and abruptly change the prognosis 
of  patients with CLD.
Therefore, the identification of  significant liver fibro-
sis and cirrhosis is essential for determining treatment 
strategies, assessing therapeutic response, and stratifying 
long-term prognosis based on the risk of  developing 
LREs. For evaluating the extent of  liver fibrosis, liver 
biopsy remains the reference standard. However, liver 
biopsies are often considered “imperfect” surrogate 
markers for liver fibrosis because of  inherent limitations, 
including invasiveness, risk of  life-threatening complica-
tions, intra- and inter-observer variability, and sampling 
error[8-11]. Moreover, monitoring the extent of  liver fibro-
sis through serial liver biopsies during antiviral or anti-
fibrotic treatments is not feasible in practice.
Accordingly, several non-invasive methods have been 
developed as alternatives to liver biopsies for evaluating 
the extent of  liver fibrosis in patients with CLDs. Alter-
native approaches include measuring serum hyaluronic 
acid levels, the ratio of  aspartate aminotransferase (AST) 
to alanine aminotransferase (ALT), AST-to-platelet 
ratio index (APRI), age-spleen-platelet ratio index (AS-
PRI), Fibrosis-4 (FIB-4), Forns’ index, Fibrotest (FT), 
FIBROSpect, Hepascore, Lok index, European Liver 
Fibrosis (ELF) panel scoring system, and transient elas-
tography (TE, FibroScan®)[12-25]. The diagnostic perfor-
mance of  these non-invasive methods has been assessed 
in many cross-sectional studies by comparing the area-
under-the-receiver operating curves (AUROCs) for these 
methods with the histological fibrosis stage as a refer-
ence standard. Accordingly, some of  these tools have 
demonstrated clinical accuracy for diagnosing significant 
fibrosis or cirrhosis and have provided reproducible and 
reliable results[26-30].
However, liver biopsy is not a perfect surrogate end-
point marker for the aforementioned reasons. Thus, 
non-invasive methods cannot be fully validated through 
cross-sectional studies[31]. Recent studies have focused 
on assessing the performance of  non-invasive methods 
through long-term, longitudinal, follow-up studies with 
solid clinical endpoints related to advanced stages of  
liver fibrosis and cirrhosis, including liver failure, hepatic 
decompensation, development of  HCC, and/or liver-
related death. These longitudinal studies do more than 
simply comparing the AUROCs with an imperfect histo-
logical reference. They also help to establish the clinical 
importance of  non-invasive methods, including predic-
tion of  long-term prognosis[31,32]. Recent studies suggest 
that serial assessments of  non-invasive methods reflect 
changes in the risk of  developing LREs in patients with 
CLD[33]. Thus, non-invasive methods are proposed to 
be valuable tools for monitoring changes in prognosis, 
which cannot be assessed with a liver biopsy.
In this article, we will summarize recent longitudinal 
studies of  non-invasive methods for predicting forth-
coming complications related to liver cirrhosis, such as 
hepatic decompensation, liver failure, development of  
HCC, or liver-related death. We will also discuss the clin-
ical value of  currently available non-invasive methods 
based on evidence from the literature. Finally, we will 
discuss future research directions.
TRaNsIeNT elasTOgRaphy
Measurement of  liver stiffness (LS) by TE has been 
proposed as a new non-invasive method for assessing 
the degree of  liver fibrosis. The ability of  TE to predict 
development of  cirrhosis-related complications has also 
been explored in several prospective, longitudinal studies 
(Table 1).
Gastroesophageal varices
An important cirrhosis-related complication is the de-
velopment of  gastroesophageal varices and bleeding. 
Gastroesophageal varices are present in 30%-60% of  
patients with liver cirrhosis. Variceal bleeding is an in-
dependent predictor of  mortality[34-36]. Although several 
cross-sectional studies[37-42] have reported significant cor-
relations between TE and the presence of  esophageal 
varices (EVs) and/or EV bleeding, the performance of  
TE alone as a predictor of  EVs is far from satisfactory. 
Thus, it has been suggested that TE alone cannot replace 
esophagogastroduodenoscopy for identifying patients 
with EVs[43]. A novel prediction model was recently in-
troduced by Kim et al[44]. This model combines TE with 
different pathophysiological parameters of  liver cirrho-
sis. The LS-spleen diameter to platelet ratio score (LSPS) 
combines the LS measurement obtained by TE with the 
spleen diameter measured by ultrasonography and the 
platelet count from a routine complete blood count. The 
LSPS has excellent accuracy for diagnosing and predict-
ing high-risk EVs in patients with compensated hepatitis 
B virus-related CLD (AUROC = 0.953; negative predic-
tive value 94.7%, positive predictive value 93.3%).
Based on a follow-up prospective, longitudinal study, 
Kim et al[45] concluded that LSPS is a reliable method for 
predicting variceal bleeding in hepatitis B virus-related 
liver cirrhosis. In this study, patients with LSPS ≥ 5.5 
showed higher cumulative incidences of  EV bleeding 
during the follow-up period. Among those with high-
risk EVs, those with an LSPS ≥ 6.5 were at an increased 
risk of  developing variceal bleeding (Figure 1).
The clinical significance of  LSPS for predicting EVs 
in patients with compensated cirrhosis of  different eti-
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Table 1  Description of prognostic studies assessing non-invasive tools for the prediction of forthcoming cirrhosis-related complications
ologies was further confirmed by Berzigotti et al[46]. In 
this European multi-center study, which included a train-
ing set of  117 patients and a validation set of  56 patients 
with compensated cirrhosis, LSPS showed good diag-
nostic performance for predicting the presence of  EVs 
(AUROC = 0.882; negative predictive value 90.8%, posi-
tive predictive values 73.2%). Patients with LSPS ≥ 3.21 
were considered to have EVs with an accuracy of  84.6% 
in the training set and 75.0% in the validation set. Inter-
estingly, whereas the diagnostic performance of  LSPS 
by AUROC was similar between the two studies[45,46], the 
cut-offs were different: 5.5 vs 3.21. The disparity between 
cut-offs is presumably due to differences in the etiolo-
gies of  the CLDs. The original publication consisted of  
patients with hepatitis B virus-related liver cirrhosis only, 
whereas the latter study included patients with liver cir-
rhosis of  various etiologies, mainly hepatitis C virus. The 
cross-sectional utility of  LSPS demonstrated in Asian 
studies was validated in a European multicenter trial. 
However, similar to variceal bleeding, the utility of  LSPS 
as a long-term prognostic factor should be validated 
through longitudinal, prospective studies performed by 
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Ref. Etiology of liver disease n Assessment modality1 Endpoint AUROC
Kim et al[45] LC (HBV)   577 LSPS Esophageal variceal bleeding 0.929
Berzigotti et al[46] LC (mostly HCV) 117 (T)/
56 (V)
LSPS, platelet count, 
spleen diameter, LS
Esophageal varices 0.882 (T), 0.808 (V)
Clinically significant portal hypertension 0.918 (T), 0.906 (V)
Masuzaki et al[49] CLD (HCV)   866 LS Hepatocellular carcinoma N/A
Jung et al[33]    LC (HBV) 1130 LS Hepatocellular carcinoma N/A
Kim et al[50]    LC (HBV)   217 LS, LSPS Hepatic decompensation 0.773 (LS); 0.790 (LSPS)
Kim et al[51] CLD (HBV)   128 LS Liver-related events 0.772
Chon et al[52] CLD (HBV) 1126 LS, LSPS, Hepatocellular carcinoma 0.789 (LS); 0.790 (LSPS)
ASPRI, P2/MS, FIB-4 Hepatic decompensation 0.820 (LS); 0.848 (LSPS)
Kim et al[53] CLD (HBV) on antiviral 
therapy
  162 LS Liver-related events 0.736
Kim et al[54] LC (HBV) on antiviral 
therapy
  103 LS Liver-related events N/A
2Singh et al[56]     CLD (various) 7058 LS Liver-related events N/A
Parkes et al[58]     CLD (various)   457 ELF Liver-related events 0.82
Kim et al[62] CLD (HBV)   170 ELF Liver-related events   0.808
Vergniol et al[66] CLD (HCV) 1457 FT, LS, APRI, FIB-4, 
LB
Overall survival (5-yr)           0.861 (FT)
de Ledinghen et al[67] CLD (HBV)   600 FT, LS, APRI, FIB-4, 
LB
Overall survival (5-yr)         0.82 (FT)
Park et al[68] CLD (HBV)   151 FT, LS, FT + LS, FT × 
LS, LB
Liver-related events 0.748 (FT + LS); 
0.868 (FT × LS)
3Morishita et al[77]    LC (HCV)   135 ARFI (LS) Esophageal varices (high-risk)               0.890 (0.868)
3Takuma et al[78] LC (mostly HCV)   340 ARFI (SS, LS) Esophageal varices (high-risk)               0.993 (0.930)
1Bold face denotes main assessment modality; 2Meta-analysis; 3Cross-sectional study. AUROC: Area-under-the-receiver-operating curve; LC: Liver cirrho-
sis; CLD: Chronic liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; T: Training set; V: Validation set; LSPS: Liver stiffness-spleen diameter to 
platelet ratio score; LS: Liver stiffness; ASPRI: Age-spleen-platelet ratio index; ELF: European Liver Fibrosis; FT: Fibrotest; APRI: Aspartate aminotransfer-
ase to platelet ratio index; ARFI: Acoustic radiation force impulse; SS: Spleen stiffness; N/A: Not available. 
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Figure 1  Cumulative incidence rate of variceal bleeding based on liver stiffness measurement-spleen diameter to platelet ratio score values. Reproduced 
with permission from Kim et al[45]. A: Among patients with liver cirrhosis related to hepatitis B virus, those with higher LSPS values had significantly higher cumulative 
incidences of bleeding from EVs during the follow-up period; n = 577; B: Among patients with high-risk EVs, patients with LSPS ≥ 6.5 had higher risks for variceal 
bleeding; n = 150. LSPS: Liver stiffness measurement-spleen diameter to platelet ratio score; EV: Esophageal varice.
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multiple investigators in patients of  varying ethnicities 
and disease etiologies.
Hepatocellular carcinoma
Advanced liver fibrosis and cirrhosis are regarded as 
major risk factors for the development of  HCC. Early 
detection of  HCC is critical for successful treatment[47,48]. 
In addition to the clinical application of  TE for diagnos-
ing the extent of  liver fibrosis and predicting the de-
velopment of  gastroesophageal varices and hepatic de-
compression, recent studies suggest that TE can predict 
the development of  HCC. Masuzaki et al[49] performed 
a large, prospective cohort study to assess the ability of  
TE to predict the development of  HCC among Japanese 
patients with hepatitis C-related liver cirrhosis. In addi-
tion to age, male gender, and clinical cirrhosis, the LS 
value stratified by TE was identified as an independent 
risk factor for developing HCC. Compared to patients 
with LS values ≤ 10 kPa, patients with higher LS values 
had a significantly increased risk of  developing HCC (LS 
values, 10.1-15 kPa, HR = 16.7; LS values, 15.1-20 kPa, 
HR = 20.9; LS values, 20.1-25 kPa, HR = 25.6; and LS 
values > 25 kPa, HR = 45.5). In addition, the cumula-
tive incidence of  HCC increased in a step-wise manner 
according to the stratified LS value (Figure 2A). These 
findings suggested that a greater extent of  liver fibrosis, 
as assessed by higher LS values, was closely associated 
with an increased risk of  developing HCC. Thus, TE is 
a clinically useful method for predicting development of  
HCC.
The clinical role of  TE for predicting the develop-
ment of  HCC was further validated in patients with liver 
cirrhosis of  different etiologies. Jung et al[33] conducted a 
study in Korean patients with chronic hepatitis B. In this 
large, prospective cohort study, a significant step-wise 
association was confirmed between LS values and the 
risk of  developing HCC. Compared to patients with LS 
values ≤ 8 kPa, patients with higher LS values had sig-
nificantly increased risks of  developing HCC (LS values, 
8.1-13 kPa, HR = 3.07; LS values, 13.1-18 kPa, HR = 4.68; 
LS values, 18.1-23 kPa, HR = 5.55; and LS values > 23 
kPa, HR = 6.60). The diagnosis of  liver cirrhosis may 
show conflicting results based on TE findings and clini-
cal criteria. Patients diagnosed with liver cirrhosis based 
on TE findings showed increased risks of  developing 
HCC than those diagnosed with liver cirrhosis based 
on clinical criteria (3.26% vs 0.87% per person-year) 
(Figure 2B). These findings indicate that TE might be a 
more precise indicator of  compensated liver cirrhosis in 
comparison to clinical criteria. Furthermore, changes in 
the risk of  developing HCC according to the pattern of  
changes in LS values were observed in the study. These 
data suggest that serial TE measurement may be a dy-
namic monitoring tool for estimating the risk of  devel-
oping HCC in patients with liver cirrhosis.
These two large studies confirmed the clinical impli-
cations of  TE as a non-invasive tool for assessing the 
risk of  developing HCC. However, incorporation of  TE 
into the routine surveillance strategy should be further 
investigated to determine if  this increases the accuracy 
of  detecting risk.
Hepatic decompensation and liver-related events
Development of  overall hepatic decompensation, not 
merely variceal bleeding, is another critical factor related 
to morbidity in advanced stages of  liver fibrosis and cir-
rhosis. Hence, early prediction of  hepatic decompensa-
tion is important for establishing therapeutic plans. Kim 
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Figure 2  Cumulative incidence of hepatocellular carcinoma. A: The cumulative incidence of hepatocellular carcinoma (HCC) showed a step-wise increase ac-
cording to the stratified liver stiffness (LS) measurement; n = 866. Reproduced with permission from Masuzaki et al[49]; B: Patients with higher LS values had signifi-
cantly higher risks of developing HCC. Transient elastography (TE) and clinical criteria produced conflicting results for diagnosing liver cirrhosis. Patients diagnosed 
with liver cirrhosis based on TE findings were at higher risk of developing HCC than those diagnosed by clinical criteria (3.26% vs 0.87% per person-year); n = 1110. 
Reproduced with permission from Jung et al[33].
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et al[50] conducted a prospective, longitudinal study to 
assess the abilities of  TE and LSPS to predict the first 
event of  hepatic decompensation in patients with liver 
cirrhosis. The study included patients with cirrhosis re-
lated to hepatitis B virus without histories of  hepatic de-
compensation, which was defined as a newly-developed 
ascites, hepatic encephalopathy, variceal bleeding, and/or 
deterioration of  liver function to Child-Pugh class B or C. 
The risk of  hepatic decompensation was stratified into 
three groups based on the LS or LSPS value. The results 
suggested that patients with higher LS values (13-18 and 
≥ 18 kPa) had significantly higher risks of  developing 
hepatic decompensation compared to those with lower 
values (< 13 kPa) (HR = 4.547, P = 0.044 and HR = 
12.446, P < 0.001, respectively). Similarly, the risk of  
developing hepatic decompensation was increased in 
patients with higher LSPS values (1.1-2.5 and ≥ 2.5) 
compared to those with lower values (< 1.1) (HR = 5.796, 
P = 0.004 and HR = 13.618, P < 0.001, respectively).
Another study[51] investigated the potential role of  
TE for predicting the development of  overall LREs 
in patients with hepatitis B virus-related CLD. Overall 
LREs included HCC, hepatic decompensation, and liver-
related mortality. In this prospective study, 128 patients 
with chronic hepatitis B who were receiving antiviral 
therapy and had histologically-confirmed advanced liver 
fibrosis (≥ F3) and high viral loads (pre-treatment levels 
of  HBV DNA ≥ 2000 IU/mL) were stratified into two 
groups based on the optimal cut-off  (19 kPa). The pa-
tients with high LS values (≥ 19 kPa) had an increased 
risk of  developing LREs compared with those who had 
lower LS values (< 19 kPa) (HR = 7.176; P = 0.001). 
The incidence of  LREs in patients with F3 and F4 were 
not statistically different (22.2% vs 13.6%; P = 0.472). 
However, there was a significant difference in the inci-
dence of  LREs between patients with higher and lower 
LS values (44.4% in ≥ 19 kPa vs 6.9% in < 19 kPa; P 
< 0.001). These results suggest that TE has superior 
performance for predicting LREs compared to that of  
histology for predicting long-term prognosis.
The role of  TE-based non-invasive tools for predict-
ing development of  cirrhosis-related events was also 
analyzed in another study[52]. In this prospective study, 
the LS values and LSPS showed good performance for 
predicting the development of  HCC (AUROC, 0.789 for 
LS value, 0.788 for LSPS) and hepatic decompensation 
(AUROC, 0.820 for LS value, 0.848 for LSPS). Further-
more, the LS value and LSPS were identified as indepen-
dent predictors of  HCC (HR = 1.040 for LS value, 1.001 
for LSPS) and hepatic decompensation (HR = 1.033 for 
LS value, 1.002 for LSPS).
Antiviral treatments are actively administered to 
patients with hepatitis B virus. It is important to un-
derstand if  TE can predict the long-term prognosis of  
patients with advanced liver fibrosis or cirrhosis who 
are being treated for hepatitis B viral infection. Recently, 
there were two publications attempting to answer this 
issue. One study[53] indicated that the LS value can pre-
dict the development of  LREs in patients with chronic 
hepatitis B receiving entecavir therapy. Another prospec-
tive, longitudinal study[54] showed that stratified LS val-
ues based on the Laennec system for histologically sub-
classifying liver cirrhosis[55] and dynamic changes in LS 
values at follow up were significantly related to different 
risks of  developing LREs in patients with advanced liver 
fibrosis who were receiving antiviral therapy for chronic 
hepatitis B virus infection.
Recently, Singh et al[56] performed a comprehensive 
meta-analysis of  17 prospective cohort studies and con-
firmed the association between LS values and LREs in 
patients with CLDs. According to this meta-analysis, a 
greater degree of  LS was significantly associated with 
an increased risk of  developing LREs, including hepatic 
decompensation (RR = 1.07), HCC (RR = 1.11), overall 
mortality (RR = 1.22), or a composite of  these events 
(RR = 1.32). Furthermore, a high LS value predicted 
the development of  liver-related events, such as hepatic 
decompensation, HCC, and overall mortality, in a dose-
dependent manner.
Thus, in addition to identifying liver fibrosis, TE ap-
pears to accurately predict long-term prognosis. How-
ever, several issues, such as determination of  cut-off  
values, TE measurement interval, and cost-effectiveness, 
remain unresolved.
elF sCORINg sysTem
Serum levels of  extracellular matrix proteins and degra-
dation products are increased in advanced liver fibrosis. 
The Original European Liver Fibrosis (OELF) panel of  
serum markers (aminoterminal propeptide of  procol-
lagen type Ⅲ, hyaluronic acid, and tissue inhibitor of  
matrix metalloproteinases-1), which reflects the dynam-
ics of  liver fibrosis, was combined with age in 2004[23]. It 
showed good diagnostic accuracy for evaluating liver fi-
brosis in CLDs of  different etiologies[23]. Later, this pan-
el was simplified to the ELF scoring system by removing 
age as a factor from the OELF panel, and the diagnostic 
accuracy remained intact[57]. ELF accurately predicted 
the extent of  liver fibrosis in several cross-sectional vali-
dation studies[58-61]. However, there are limited studies on 
the longitudinal performance of  the ELF scoring system 
for predicting LREs in patients with liver cirrhosis be-
yond the cross-sectional aspects of  ELF.
Parkes et al[58] investigated the performance of  the 
ELF scoring system for predicting the development of  
LREs in Caucasian patients with diverse etiologies of  
CLDs using paired ELF scores and liver biopsy data. In 
this multi-center study from the United Kingdom, the 
study population was stratified into four groups accord-
ing to the ELF score for precise assessment of  the risk 
of  developing LREs. The performance of  the ELF scor-
ing system was compared with that of  histopathology of  
a liver biopsy. The fully adjusted HRs for LREs showed 
a graded response according to the stratified ELF-score 
group. Compared to patients with ELF scores < 8.34, 
2617 March 14, 2014|Volume 20|Issue 10|WJG|www.wjgnet.com
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patients with higher ELF scores had significantly higher 
risks of  developing LREs (ELF score, 12.52-16.67, HR 
= 75; ELF score, 10.426-12.51, HR = 20; and ELF 
score, 8.34-10.425, HR = 5) (Figure 3). Similarly, com-
pared to patients with no fibrosis or mild fibrosis on liv-
er biopsies, patients with advanced liver fibrosis were at 
increased risk of  developing LREs (HR = 2.4 for mod-
erate fibrosis; 8.3 for severe fibrosis/cirrhosis). Thus, the 
ELF scoring system was better than a liver biopsy for 
predicting development of  LREs.
In addition, during the follow-up period, 82% of  pa-
tients within the highest ELF-score group (12.52-16.67) 
experienced an LRE. In contrast, only 46% of  those 
identified with severe fibrosis/cirrhosis based on a 
liver biopsy experienced an LRE. Moreover, when the 
risk of  developing an LRE was analyzed with ELF as a 
continuous variable, the fully-adjusted OR for LRE was 
2.2 (95%CI: 1.7-2.9). This result indicates that a unit 
increase in the ELF score was associated with a two-
fold risk of  developing an LRE. Furthermore, the ELF 
scoring system showed better diagnostic performance 
than a liver biopsy (AUROC, 0.82 for ELF, 0.70 for liver 
biopsy; P = 0.004) for predicting overall mortality.
Recently, the ELF scoring system was further con-
firmed to predict the development of  LREs in a pro-
spective study with a cohort of  170 Asian patients with 
hepatitis B virus-related CLDs[62]. The ELF scoring sys-
tem showed good diagnostic performance for predicting 
the development of  LREs (AUROC = 0.808). There 
was a significant association between the ELF score 
and the risk of  developing LREs (ρ = 0.449; P < 0.01). 
A unit increase in the ELF score was associated with a 
1.4-fold increase in the risk of  developing an LRE. A 
higher ELF score at enrollment was correlated with an 
increased incidence of  LREs (HR = 1.438; P < 0.001). 
Patients were subdivided into two groups based on a 
calculated optimal cut-off  of  10.1. Patients with lower 
ELF scores had significantly reduced risks of  developing 
LREs compared with those who had higher ELF scores 
(HR = 0.24; P < 0.001). Similar to the original publica-
tion[58], stratification of  patients into three groups based 
on the ELF score showed that the fully-adjusted HRs 
for LREs had a graded response. Compared to patients 
with ELF score ≥ 10.40, patients with lower ELF scores 
had significantly lower risks of  developing LREs (ELF 
score, < 8.10, HR = 0.072; and ELF score, 8.10-10.39, 
HR = 0.286). The superior diagnostic performance of  
the ELF scoring system for predicting overall mortality 
compared with a liver biopsy was also confirmed in this 
study (AUROC, 0.749 for ELF, 0.651 for liver biopsy).
Similar to TE, the ability of  ELF to predict the de-
velopment of  cirrhosis-related complications has been 
confirmed in several studies. However, the clinical utility 
of  the ELF scoring system is limited to centers at which 
extracellular matrix serum markers can be routinely mea-
sured. Thus, the general clinical applicability of  the ELF 
scoring system requires extensive validation and a cost-
effective analysis.
FIbROTesT
The FT scoring system was developed by Imbert-Bismut 
et al[17] in 2001. The system is based on a panel of  five 
serum markers, which includes α2-macroglobulin, hap-
toglobin, apolipoprotein A1, gamma-glutamyl transpep-
tidase (GGT), and total bilirubin adjusted by age and 
gender. The performance of  FT as a surrogate marker 
for liver biopsy has been extensively studied. FT is ac-
Figure 3  Kaplan-Meier analysis of liver-related events in patients stratified according to enhanced liver fibrosis scores. Reproduced with permission from 
Parkes et al[58]. The study population was stratified into four groups according to the enhanced liver fibrosis (ELF) score for precise assessment of the risks of develop-
ing liver-related events (LREs). LREs showed a graded response according to the stratified ELF score groups. Patients with higher ELF scores had significantly higher 
risks of having LREs; n = 457.
HR (95%CI)
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0                     2                      4                     6                      8
ELF score 4.16-8.33 184 170 160 134 31 1 (reference)
ELF score 8.34-10.425 203 190 178 138 29 5 (1.4, 16.9)
ELF score 10.426-12.51 53 41 36 26 5 20 (5.5, 71.0)
ELF score 12.52-16.67 17 9 5 4 1 76 (17.6, 325.4)
cepted as a promising non-invasive method with a high 
degree of  accuracy and reproducibility for predicting 
advanced liver fibrosis and cirrhosis in patients with 
CLDs[63,64]. The prognostic value of  FT for predicting 
five-year survival in patients with CLDs of  various eti-
ologies has been previously studied[65-67]. Vergniol et al[66] 
conducted a prospective five-year study to assess wheth-
er FT can predict overall survival (OS) in patients with 
chronic hepatitis C. In this study, FT showed a high level 
of  accuracy for predicting OS with an AUROC of  0.861. 
The risk of  mortality was increased with a cut-off  value 
of  7.4 (adjusted HR = 90). Furthermore, risk stratifica-
tion based on the FT score was able to predict five-year 
OS (FT, ≤ 0.75, OS = 97%; FT, 0.75-0.80, OS = 87%; 
FT, 0.81-0.85, OS = 84%; FT, 0.86-0.90, OS = 75%; FT, 
0.91-0.95, OS = 69%; and FT > 0.95, OS = 0%). Com-
parable results were observed in a similar prospective, 
single-center study in patients with chronic hepatitis B[67]. 
The prognostic performance of  FT for predicting OS 
was good with an AUROC of  0.82. The five-year OS 
rates were 96.8% for FT ≤ 0.73 and 49.2% for FT > 0.85, 
respectively.
The FT and measurement of  LS by TE have high 
degrees of  accuracy and reproducibility for predicting 
the extent of  liver fibrosis and development of  LREs 
in patients with CLDs. Thus, combined application of  
these two methods may provide additional discrimina-
tory potential for predicting LREs. Indeed, the combina-
tion of  LS and FT increased the cross-sectional diagnos-
tic performance for assessing the degree of  liver fibrosis 
and the diagnosis of  liver cirrhosis (AUROC, 0.910 
for LS only; 0.866 for FT only; 0.915 for FT + LS; and 
0.929 for FT × LS)[64]. Park et al[68] recently conducted a 
prospective five-year longitudinal study to assess if  the 
combination of  FT with LS values enhanced the overall 
performance of  predicting LREs in patients with hepa-
titis B virus-related liver cirrhosis. The combination was 
calculated as either the sum or multiplication of  the FT 
score and LS values (FT + LS or FT × LS, respectively). 
In this study, 151 patients were analyzed, and the time-
dependent AUROCs for predicting LREs were 0.748 
(95%CI: 0.621-0.868) and 0.785 (95%CI: 0.647-0.906) 
at five-year follow-ups of  FT + LS and FT × LS, re-
spectively. Data were adjusted for age and histological 
fibrosis staging, which were the two significant factors 
according to univariate analysis (P < 0.05). Multivariate 
analysis revealed that FT + LS and FT × LS were inde-
pendent predictors of  LREs (P = 0.001, HR = 1.116; 
P = 0.001, HR = 1.137, respectively). Stratification of  
the study population into three groups showed that the 
cumulative risk of  developing LREs was significantly 
graded according to the stratification. The study popula-
tion was stratified with cut-off  values of  9.4 and 17.5 for 
the FT + LS analysis. The cumulative incidence rates of  
developing LREs at 2, 3, and 5 years were 2.1%, 4.4%, 
and 6.7%, respectively, for the low group (FT + LS < 
9.4); 3.9%, 6.7%, and 13.0%, respectively, for the inter-
mediate group (FT + LS 9.4-17.5); and 8.0%, 12.2%, 
and 16.8%, respectively, for the high group (FT + LS > 
17.5) (P = 0.029). Similarly, for the FT × LS analysis, the 
study population was stratified with cut-off  values of  3.6 
and 11.0. The cumulative incidence rates of  developing 
LREs at 2, 3, and 5 years were 1.8%, 2.7%, and 4.5%, re-
spectively, for the low group (FT × LS < 3.6); 3.8%, 6.1%, 
and 14.2%, respectively, for the intermediate group (FT 
× LS 3.6-11.0); and 8.3%, 12.8%, and 17.5%, respec-
tively, for the high group (FT × LS > 11.0) (P = 0.008).
The prognostic role of  FT was demonstrated ex-
clusively in a French study of  a cohort of  patients with 
chronic hepatitis C. Thus, the clinical value of  FT requires 
further validation in a diverse population of  patients with 
CLDs of  varying etiologies. Fortunately, the prognostic 
performance of  FT has recently been demonstrated in 
several Asian studies of  a cohort of  patients with chronic 
hepatitis B in cross-sectional and longitudinal studies[64,69]. 
Based on current findings, further research is warranted 
to define the clinical utility of  FT for predicting the long-
term prognosis of  patients with liver cirrhosis.
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Figure 4  Cumulative rate of liver-related events in patients stratified according to the combination of Fibrotest and liver stiffness values. Reproduced with 
permission from Park et al[68]. The study population was stratified into three groups according to FT + LS (A) and FT × LS (B) values for precise assessment of the risk 
of developing LREs. The cumulative risk of developing LREs showed a significant graded response according to the stratified groups in both FT + LS (P = 0.029) and 
FT × LS (P = 0.008) analyses. n = 151. FT: Fibrotest; LS: Liver stiffness; LRE: Liver-related event. 
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OTheR mODels
Several simple non-invasive methods including APRI, 
FIB-4, Forns’ index and Lok index have been found to 
be useful in assessing the extent of  fibrosis in patients 
with CLD. Given their universal availability without ad-
ditional economic burden, several studies evaluated the 
clinical significance of  these simple non-invasive scoring 
systems for prediction of  forthcoming complications 
related to liver cirrhosis. 
A retrospective, multicenter, large-scale study of  cir-
rhotic patients by Sebastiani et al[70] demonstrated that 
a combination of  the Lok index and the Forns’ index 
had a high negative predictive value (> 90%) to exclude 
clinically relevant EVs with an AUROC of  0.80, and 
suggested that these non-invasive markers may be use-
ful as an initial screening tool for cirrhotic patients to 
exclude the presence of  clinically relevant EVs. Another 
study by Angulo et al[71] showed that simple non-invasive 
methods including APRI and FIB-4 can identify patients 
with nonalcoholic fatty liver disease at higher risk for de-
velopment of  LREs and higher overall mortality. How-
ever, due to the limitations inherent in the retrospective 
studies, the clinical value of  these non-invasive methods 
needs to be further validated in additional large-scale, 
prospective, and preferably, longitudinal studies.
Acoustic radiation force impulse (ARFI) elastography 
is a novel technology based on conventional B-mode 
ultrasonography, which provides numeric measurements 
of  tissue stiffness as the shear wave velocity[72]. Several 
publications suggest that LS values and spleen stiffness 
measured by ARFI elastography both correlate well with 
the extent of  liver fibrosis in patients with CLDs[73-75]. 
The role of  ARFI elastography for assessing the risk of  
cirrhosis-related complications has been investigated in 
several studies[76-79].
A recent cross-sectional study by Morishita et al[77] 
showed that LS measurements by ARFI elastography 
predicted the presence of  EVs (cut-off  value of  2.05 
m/s) or high-risk EVs (cut-off  value of  2.39 m/s) in 
patients with hepatitis C virus-related liver cirrhosis. 
The diagnostic performance of  this method was good 
(AUROC, 0.890 for EVs; 0.868 for high-risk EVs) with 
a high negative-predictive value (81% for EVs; 89% for 
high-risk EVs) and an acceptable positive-predictive 
value (78% for EVs; 69% for high-risk EVs).
In addition, a study by Bota et al[79] proposed a scor-
ing system for predicting high-risk EVs based on liver 
stiffness and spleen stiffness assessed by ARFI elastogra-
phy. The diagnostic performance of  this scoring system 
was acceptable (AUROC = 0.721), yet further validation 
is desired.
Several studies[78,80] also reported that spleen stiffness 
measurement by TE can provide non-invasive assess-
ment of  the presence of  EVs in patients with liver cir-
rhosis. Recently, a prospective study by Takuma et al[78] 
showed that spleen stiffness assessed by ARFI elastog-
raphy was able to predict the presence of  EVs (cut-off  
value of  3.18 m/s) or high-risk EVs (cut-off  value of  
3.30 m/s) in patients with liver cirrhosis. This method 
showed excellent diagnostic performance (AUROC, 0.933 
for EVs; 0.930 for high-risk EVs) and a high negative-
predictive value (98.4% for EVs; 99.4% for high-risk 
EVs). However, the positive-predictive value was low 
(61.0% for EVs; 47.8% for high-risk EVs). In contrast, 
Vermehren et al[81] reported that the diagnostic perfor-
mance of  spleen stiffness measured by ARFI elastogra-
phy for predicting large EVs was not satisfactory (AU-
ROC = 0.58). Moreover, Mori et al[82] showed that there 
was no significant association between spleen stiffness 
measured by ARFI elastography and the presence of  
EVs in patients with chronic hepatitis C. Furthermore, a 
recent meta-analysis conducted by Singh et al[83] showed 
that the current techniques of  spleen stiffness measure-
ment - either by ARFI or TE - are suboptimal for pre-
dicting EVs in patients with CLDs. Hence, further well-
designed prospective studies are desired for evaluating 
the diagnostic role of  spleen stiffness measurement in 
predicting EVs.
There have been no longitudinal studies of  the role 
of  LS measurements by ARFI elastography and spleen 
stiffness measurements with TE or ARFI elastography 
for risk assessment of  LREs in patients with CLDs. 
Therefore, longitudinal, multi-center studies are warrant-
ed to establish a standardized protocol for measuring LS 
values by ARFI elastography and spleen stiffness by TE 
or ARFI elastography. Further studies are also needed to 
validate the clinical role of  these non-invasive tools for 
assessing the risk of  liver cirrhosis-related complications.
CONClUsION
The current view from a limited number of  studies is 
that the recently-introduced non-invasive models can 
independently predict future cirrhosis-related compli-
cations, such as hepatic decompensation, liver failure, 
HCC, or liver-related death. In addition, some non-inva-
sive tools, such as TE or TE-based models (i.e., LSPS), 
appear to exhibit superior performance compared to 
histology and other non-invasive methods for predicting 
development of  LREs.
Non-invasive models may no longer simply be tools 
for predicting the extent of  fibrosis in patients with 
CLDs. Instead, current literature supports the use of  
these methods as surveillance tools for predicting future 
LREs and determining long-term prognosis, which will 
help to make informed treatment decisions. Future stud-
ies should assess whether serial changes in non-invasive 
measurements or scores reflect the dynamic changes in 
the risk of  developing LREs. In addition, the combina-
tion of  two or more non-invasive methods should be 
tested to determine if  this approach provides greater 
discriminatory power for predicting LREs. Significant 
progress in this field will allow new strategies for risk 
management in patients with CLD to be developed in 
the near future.
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